| |
| |
Patent 7,172,763 |
 | | The neurotoxin can be a botulinum toxin, such as one of the botulinum toxin types A, B, C.sub.1, D, E, F or G. Preferably the botulinum toxin is botulinum toxin type A. The neurotoxin can be a modified neurotoxin which has at least one amino acid deleted, modified or replaced. |
 | | The neurotoxins within the scope of the present invention exclude neuronal targeting moieties which are not native to the neurotoxin because we have found that the present invention can be effectively practiced without the necessity of making any modification or deletions to the native or wild type binding moiety of the neurotoxins used. |
 | | The neuronal binding moiety component of the neurotoxin is a neuronal binding moiety which is native to the selected neurotoxin because we have discovered that the present invention can be practiced without replacement of the wild type neuronal binding moiety with a non-native or non wild type targeting moiety. |
| www.pharmcast.com /Patents100/Yr2007/Feb2007/020607/7172763_Neurotoxin020607.htm (4667 words) |
|